还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

% w5 ?7 l7 c2 n& Y! ~. J7 \可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
# h% ]5 ~$ w2 z$ M. [1 b3 k: Z& ~

Sub-category:
0 d) Y6 g  v+ P+ S0 r3 R$ QMolecular Targets

% Z# u0 j4 t: c3 [9 }) [0 z0 ^+ f
" H3 D  `5 e; oCategory:
4 I1 d# Z* S3 W" v3 eTumor Biology


Meeting:
2011 ASCO Annual Meeting
) x: c3 f5 u/ k5 P, `2 Z

Session Type and Session Title:
" h/ ~2 ?1 J  u  K8 o6 EPoster Discussion Session, Tumor Biology
- z7 \6 V9 |; O* N$ t. _  W
( Q9 \( z- K# \) I
$ T5 c0 i. D1 E( a, ^' r& tAbstract No:
10517


Citation:
$ J9 N5 m! `- |5 hJ Clin Oncol 29: 2011 (suppl; abstr 10517)
8 L* X) G/ e& ^3 K* D

Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

* n! \2 ]% N+ I% S3 q+ O

- S. e9 m  @9 xAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
$ @0 n, S5 E1 I$ y- M' {: y- q- e$ W
Abstract Disclosures

% U0 i$ h7 @( W# f5 UAbstract:

; v7 n) L- }6 z
. Z' f9 ?" E4 l% g% ~0 z5 GBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

% ?0 r" V# g( ^! U! B% }7 B没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

" p, S" x6 M4 ]; c' a6 J化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
8 \, W* s5 p, w7 |/ V6 U; pALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
" |6 [/ O7 ~$ V. c0 Y1 w2 C8 _
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊